Đánh giá một thuật toán mới không dựa vào cystatin-C để tính toán tỷ lệ lọc cầu thận cá nhân ở bệnh nhân ung thư nhận carboplatin

Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147 Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1, 1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432–5438 Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528 Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R (1993) Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156–1164 Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756 Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L, Gumbrell L, Thomas H, Chapman F (1995) Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91–98 Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG (2004) Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291–295 Poole SG, Dooley MJ, Rischin D (2002) A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 13:949–955 Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41 Jelliffe RW (1973) Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604–605 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470 Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84:1053–1060 Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452–459 Holweger K, Lipp HP, Dietz K, Hartmann JT, Bokemeyer C (2008) Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 42:1749–1757 Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18:2024–2031 Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E (2009) A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 15:3633–3639 Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324–327 van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351:777–781 Du BD, Du Bois EF (1919) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303–311 Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R, Canal P (1995) Prediction of carboplatin clearance from morphological and biological patient characteristics. Bull Cancer 82:946–953 Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953 Corcoran RM, Durnan SM (1977) Albumin determination by a modified bromcresol green method. Clin Chem 23:765–766 Finney H, Newman DJ, Gruber W, Merle P, Price CP (1997) Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 43:1016–1022 Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310 Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14–34 Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G (2007) Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376–1384 Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483 Holweger K, Bokemeyer C, Lipp HP (2005) Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 131:559–567 Dooley MJ, Poole SG, Rischin D, Webster LK (2002) Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 38:44–51 Ekhart C, de Jonge Milly E, Huitema Alwin DR, Schellens JHM, Rodenhuis S, Beijnen Jos H (2006) Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 12:6502–6508 Bookstaver PB, Johnson JW, McCoy TP, Stewart D, Williamson JC (2008) Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Ann Pharmacother 42:1758–1765 Kos J, Stabuc B, Cimerman N, Brunner N (1998) Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44:2556–2557 Louvar DW, Rogers TB, Bailey RF, Matas AJ, Ibrahim HN (2007) Cystatin C is not superior to creatinine-based models in estimating glomerular filtration rate in former kidney donors. Transplantation 84:1112–1117 Donadio C, Lucchesi A, Ardini M, Cosio S, Fanucchi A, Gadducci A (2009) Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer. Ther Drug Monit 31:63–69